{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T07:42:29Z","timestamp":1769067749844,"version":"3.49.0"},"reference-count":43,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>This review provides updates regarding biomarker studies that address key clinical unmet needs, which relate to the evaluation of the disease activity in patients with dermatomyositis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>Increasing evidence supports that the serum levels of dermatomyositis-specific antibodies (DM-MSAs), which include anti-Mi-2, anti-NXP2, anti-MDA5, anti-TNF1-\u03b3, and anti-SAE, are correlated with the disease activity. Moreover, serial measurements of DM-MSA levels may help to predict the disease status. Beyond the MSA, macrophage activation-related biomarker-soluble CD163, CD206, neopterin, and galectin-3\/9 are the most currently talked biomarkers for disease activity in dermatomyositis; new circulating T-cell subsets CD4+CXCR5+CCR7loPD-1hi and TIGIT+CD226+ CD4 T cells can potentially harbor biomarkers of disease activity in dermatomyositis. In addition, LDGs and NETs were also shown to be correlated with the disease activities of dermatomyositis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>Promising candidate biomarkers are now available for evaluating disease activity in dermatomyositis. These biomarkers need external validation in other large cohort studies.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/bor.0000000000000905","type":"journal-article","created":{"date-parts":[[2022,9,9]],"date-time":"2022-09-09T10:07:11Z","timestamp":1662718031000},"page":"289-294","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":11,"title":["Biomarkers of disease activity in dermatomyositis"],"prefix":"10.1097","volume":"34","author":[{"given":"Xin","family":"Lu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qinglin","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guochun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2022,8,30]]},"reference":[{"key":"R1-20250526","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s13317-014-0060-4","article-title":"Myositis autoantibodies and clinical phenotypes","volume":"5","author":"Ghirardello","year":"2014","journal-title":"Auto Immun Highlights"},{"key":"R2-20250526","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.nmd.2019.10.005","article-title":"239th ENMC International Workshop: classification of dermatomyositis, Amsterdam, the Netherlands, 14\u201316 December","volume":"30","author":"Mammen","year":"2020","journal-title":"Neuromuscul Disord"},{"issue":"(Suppl 11)","key":"R3-20250526","first-page":"S118","article-title":"Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: Physician and Patient\/Parent Global Activity, Manual Muscle Testing (MMT), Health Assess- ment Questionnaire (HAQ)\/Childhood Health Assessment Questionnaire (C-HAQ), Childhood Myositis Assessment Scale (CMAS), Myositis Disease Activity Assessment Tool (MDAAT), Disease Activity Score (DAS), Short Form 36 (SF-36), Child Health Questionnaire (CHQ), Physician Global Damage, Myositis Damage Index (MDI), Quantitative Muscle Testing (QMT), Myositis Functional Index-2 (FI-2), Myositis Activities Profile (MAP), Inclusion Body Myositis Functional Rating Scale (IBMFRS), Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI), Cutaneous Assessment Tool (CAT), Dermatomyositis Skin Severity Index (DSSI), Skin- dex, and Dermatology Life Quality Index (DLQI)","volume":"63","author":"Rider","year":"2011","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R4-20250526","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/s41572-021-00321-x","article-title":"Idiopathic inflammatory myopathies","volume":"7","author":"Lundberg","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"R5-20250526","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1093\/rheumatology\/kev444","article-title":"Autoantibody levels in myositis patients correlate with clinical response during B cell depletion with rituximab","volume":"55","author":"Aggarwal","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"R6-20250526","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1684\/ejd.2020.3750","article-title":"Anti-Mi-2 autoantibodies characterize a distinct clinical subset of dermatomyositis with favorable prognosis","volume":"30","author":"Lin","year":"2020","journal-title":"Eur J Dermatol"},{"key":"R7-20250526","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1002\/art.40491","article-title":"Differential clinical associations of antinuclear matrix protein-2 autoantibodies in patients with idiopathic inflammatory myopathies","volume":"70","author":"Yang","year":"2018","journal-title":"Arthritis Rheum"},{"key":"R8-20250526","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1093\/rheumatology\/kex188","article-title":"Clinical characteristics and change in the antibody titres of patients with anti-MDA5 antibody positive inflammatory myositis","volume":"56","author":"Yoshiyuki","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"R9-20250526","doi-asserted-by":"crossref","first-page":"3284","DOI":"10.1093\/rheumatology\/keaa123","article-title":"Efficacy of plasma exchange in anti-MDA5-positive dermatomyositis with interstitial lung disease under combined immunosuppressive treatment","volume":"59","author":"Mirei","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"R10-20250526","first-page":"keac229","article-title":"Evaluation and validation of the prognostic value of anti-MDA5 IgG subclasses in dermatomyositis-associated interstitial lung disease","author":"Xu","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"R11-20250526","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1002\/art.33403","article-title":"Myositis-specific anti155\/140 autoantibodies target transcription intermediary factor 1 family proteins","volume":"64","author":"Manabu","year":"2012","journal-title":"Arthritis Rheum"},{"key":"R12-20250526","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1093\/rheumatology\/key310","article-title":"Changes in antibody titres in patients with antitranscription intermediary factor 1-gamma antibody-positive idiopathic inflammatory myositis","volume":"58","author":"Abe","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"R13-20250526","doi-asserted-by":"crossref","first-page":"152011","DOI":"10.1016\/j.semarthrit.2022.152011","article-title":"Serum levels of anti-transcriptional intermediary factor 1-\u03b3 autoantibody associated with the clinical, pathological characteristics and outcomes of patients with dermatomyositis","volume":"55","author":"Zhang","year":"2022","journal-title":"Semin Arthritis Rheum"},{"key":"R14-20250526","first-page":"67","article-title":"Antitranscriptional intermediary factor 1 gamma antibodies in cancer-associated myositis: a longitudinal study","volume":"38","author":"Dani","year":"2020","journal-title":"Clin Exp Rheumatol"},{"key":"R15-20250526","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1038\/s41598-017-00240-6","article-title":"Clinical characteristics of anti-SAE antibodies in Chinese patients with dermatomyositis in comparison with different patient cohorts","volume":"15","author":"Ge","year":"2017","journal-title":"Sci Rep"},{"key":"R16-20250526","doi-asserted-by":"crossref","first-page":"979","DOI":"10.3899\/jrheum.141307","article-title":"Elevated serum levels of soluble CD163 in polymyositis and dermatomyositis: associated with macrophage infiltration in muscle tissue","volume":"42","author":"Peng","year":"2015","journal-title":"J Rheumatol"},{"key":"R17-20250526","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s13075-016-1214-8","article-title":"Clinical significance of soluble CD163 in polymyositis-related or dermatomyositis-related interstitial lung disease","volume":"19","author":"Enomoto","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"R18-20250526","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1093\/rheumatology\/kez185","article-title":"Successful classification of macrophage-mannose receptor CD206 in severity of anti-MDA5 antibody positive dermatomyositis associated ILD","volume":"58","author":"Horiike","year":"2019","journal-title":"Rheumatlogy (Oxford)"},{"key":"R19-20250526","doi-asserted-by":"crossref","first-page":"7948095","DOI":"10.1155\/2020\/7948095","article-title":"Increased levels of soluble CD206 associated with rapidly progressive interstitial lung disease in patients with dermatomyositis","volume":"2020","author":"Shen","year":"2020","journal-title":"Mediators Inflamm"},{"key":"R20-20250526","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/cei.13404","article-title":"A high level of serum neopterin is associated with rapidly progressive interstitial lung disease and reduced survival in dermatomyositis","volume":"199","author":"Peng","year":"2020","journal-title":"Clin Exp Immunol"},{"key":"R21-20250526","doi-asserted-by":"crossref","first-page":"628128","DOI":"10.3389\/fcell.2021.628128","article-title":"Aberrantly expressed galectin-9 is involved in the immunopathogenesis of anti-MDA5-positive dermatomyositis-associated interstitial lung disease","volume":"9","author":"Liang","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"R22-20250526","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1093\/rheumatology\/keaa305","article-title":"Serum levels of galectin-3 in idiopathic inflammatory myopathies: a potential biomarker of disease activity","volume":"60","author":"Watanabe","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"R23-20250526","doi-asserted-by":"crossref","first-page":"4792","DOI":"10.4049\/jimmunol.0803688","article-title":"T cell infiltrates in the muscles of patients with dermatomyositis and polymyositis are dominated by CD28null T cells","volume":"183","author":"Fasth","year":"2009","journal-title":"J Immunol"},{"key":"R24-20250526","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1002\/art.39650","article-title":"CD4+ and CD8+ CD28(null) T cells are cytotoxic to autologous muscle cells in patients with polymyositis","volume":"68","author":"Pandya","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"R25-20250526","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/1756-185X.13782","article-title":"Aberrant expansion of circulating CD4(+) CXCR5(+) CCR7(lo) PD1(hi) Tfh precursor cells in idiopathic inflammatory myopathy","volume":"23","author":"Zhang","year":"2020","journal-title":"Int J Rheum Dis"},{"key":"R26-20250526","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s13075-020-02397-4","article-title":"Expansion of circulating peripheral TIGIT+CD226+ CD4\u200aT cells with enhanced effector functions in dermatomyositis","volume":"23","author":"Li","year":"2021","journal-title":"Arthritis Res Ther"},{"key":"R27-20250526","doi-asserted-by":"crossref","first-page":"538","DOI":"10.4049\/jimmunol.1100450","article-title":"Netting neutrophils induce endothelial damage, infiltrate tissues, and expose immunostimulatory molecules in systemic lupus erythematosus","volume":"187","author":"Villanueva","year":"2011","journal-title":"J Immunol"},{"key":"R28-20250526","doi-asserted-by":"crossref","first-page":"3284","DOI":"10.4049\/jimmunol.0902199","article-title":"A distinct subset of proinflammatory neutrophils isolated from patients with systemic lupus erythematosus induces vascular damage and synthesizes type I IFNs","volume":"184","author":"Denny","year":"2010","journal-title":"J Immunol"},{"key":"R29-20250526","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/cei.12319","article-title":"Enhanced formation and impaired degradation of neutrophil extracellular traps in dermatomyositis and polymyositis: a potential contributor to interstitial lung disease complications","volume":"177","author":"Zhang","year":"2014","journal-title":"Clin Exp Immunol"},{"key":"R30-20250526","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1080\/14397595.2016.1179861","article-title":"Abnormally increased low-density granulocytes in peripheral blood mononuclear cells are associated with interstitial lung disease in dermatomyositis","volume":"27","author":"Zhang","year":"2017","journal-title":"Mod Rheumatol"},{"key":"R31-20250526","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s10067-017-3799-y","article-title":"Neutrophil extracellular traps may contribute to interstitial lung disease associated with anti-MDA5 autoantibody positive dermatomyositis","volume":"37","author":"Peng","year":"2018","journal-title":"Clin Rheumatol"},{"key":"R32-20250526","doi-asserted-by":"crossref","first-page":"e480","DOI":"10.1097\/RHU.0000000000001772","article-title":"Low-density granulocytes and neutrophil extracellular traps as biomarkers of disease activity in adult inflammatory myopathies","volume":"28","author":"Torres-Ruiz","year":"2022","journal-title":"J Clin Rheumatol"},{"key":"R33-20250526","doi-asserted-by":"crossref","first-page":"e134189","DOI":"10.1172\/jci.insight.134189","article-title":"Neutrophil dysregulation is pathogenic in idiopathic inflammatory myopathies","volume":"5","author":"Seto","year":"2020","journal-title":"JCI Insight"},{"key":"R34-20250526","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1111\/jcmm.14858","article-title":"Neutrophil extracellular traps activate lung fibroblast to induce polymyositis-related interstitial lung diseases via TLR9-miR-7-Smad2 pathway","volume":"24","author":"Zhang","year":"2020","journal-title":"J Cell Mol Med"},{"key":"R35-20250526","doi-asserted-by":"crossref","first-page":"e1193","DOI":"10.1212\/WNL.0000000000008128","article-title":"Identification of distinctive interferon gene signatures in different types of myositis","volume":"93","author":"Pinal-Fernandez","year":"2019","journal-title":"Neurology"},{"key":"R36-20250526","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/gene.2011.61","article-title":"Relationship between disease activity and type 1 interferon- and other cytokine-inducible gene expression in blood in dermatomyositis and polymyositis","volume":"13","author":"Greenberg","year":"2012","journal-title":"Genes Immun"},{"key":"R37-20250526","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1111\/bjd.15006","article-title":"Correlation of cutaneous disease activity with type 1 interferon gene signature and interferon \u03b2 in dermatomyositis","volume":"176","author":"Huard","year":"2017","journal-title":"Br J Dermatol"},{"key":"R38-20250526","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1002\/art.40800","article-title":"Muscle expression of type I and type II interferons is increased in juvenile dermatomyositis and related to clinical and histologic features","volume":"71","author":"Moneta","year":"2019","journal-title":"Arthritis Rheum"},{"key":"R39-20250526","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/ana.20464","article-title":"Interferon-alpha\/beta-mediated innate immune mechanisms in dermatomyositis","volume":"57","author":"Greenberg","year":"2005","journal-title":"Ann Neurol"},{"key":"R40-20250526","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1212\/WNL.0000000000003568","article-title":"Sarcoplasmic MxA expression: a valuable marker of dermatomyositis","volume":"88","author":"Uruha","year":"2017","journal-title":"Neurology"},{"key":"R41-20250526","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1111\/nan.12519","article-title":"Diagnostic potential of sarcoplasmic myxovirus resistance protein A expression in subsets of dermatomyositis","volume":"45","author":"Uruha","year":"2019","journal-title":"Neuropathol Appl Neurobiol"},{"key":"R42-20250526","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.clim.2006.05.011","article-title":"MxA gene expression in juvenile dermatomyositis peripheral blood mononuclear cells: association with muscle involvement","volume":"120","author":"O\u2019Connor","year":"2006","journal-title":"Clin Immunol"},{"key":"R43-20250526","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/nan.12498","article-title":"Expression of myxovirus-resistance protein A: a possible marker of muscle disease activity and autoantibody specificities in juvenile dermatomyositis","volume":"45","author":"Soponkanaporn","year":"2019","journal-title":"Neuropathol Appl Neurobiol"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000000905","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T21:19:03Z","timestamp":1748294343000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000000905"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,30]]},"references-count":43,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000000905","relation":{},"ISSN":["1040-8711","1531-6963"],"issn-type":[{"value":"1040-8711","type":"print"},{"value":"1531-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,30]]}}}